ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Buys $89,600.00 in Stock

ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster purchased 70,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were purchased at an average price of $1.28 per share, for a total transaction of $89,600.00. Following the purchase, the director now owns 138,333 shares of the company’s stock, valued at approximately $177,066.24. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

ProMIS Neurosciences Price Performance

ProMIS Neurosciences stock traded up $0.07 during trading hours on Tuesday, reaching $1.30. The stock had a trading volume of 106,909 shares, compared to its average volume of 70,907. ProMIS Neurosciences, Inc. has a 52 week low of $0.95 and a 52 week high of $3.10. The business’s 50 day moving average price is $1.41 and its 200-day moving average price is $1.72. The company has a market cap of $24.65 million, a price-to-earnings ratio of -1.76 and a beta of 0.62.

ProMIS Neurosciences (NASDAQ:PMN) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.01. On average, sell-side analysts forecast that ProMIS Neurosciences, Inc. will post -0.24 EPS for the current fiscal year.

ProMIS Neurosciences Company Profile

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.